Tran THC, Erginay A, Verdun S, et al. - In this prospective, non-comparative, multicenter observational study, researchers sought to assess the effectiveness of intravitreal aflibercept injection (IAI) for vitrectomized eyes with diabetic macular edema (DME) at one year. Participants in the study were diabetic patients whose HbA1c is < 9%, with visual acuity between 20/400 to 20/40 due to DME, who have undergone vitrectomy since at least 3 months before the first aflibercept injection. Forty-six eyes were involved. During the study, no serious systemic adverse events were reported. Such findings imply that IAI could be beneficial in vitrectomized eyes with refractory DME that require frequent injections to achieve visual and anatomical improvement.